[Form 4] Pacira BioSciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Pacira BioSciences Chief Financial Officer Shawn Cross exercised stock options and sold shares in a pre-planned set of trades. Over April 20–22, he exercised options for 12,059 shares of common stock at an exercise price of $16.45 per share and sold the same number of shares in open-market transactions at weighted average prices around $25.01–$25.14 per share.

After these transactions, he directly holds 105,341 shares of Pacira common stock. The filing states that the option exercises and sales were carried out under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic.

Insights

Insider trading & governance analyst

Pacira’s CFO executed a routine exercise-and-sell under a 10b5-1 plan.

The filing shows CFO Shawn Cross exercised stock options for 12,059 Pacira common shares at an exercise price of $16.45 and sold the same number of shares in open-market trades around $25 over three days.

This pattern reflects an exercise-and-sell transaction, converting options into cash rather than increasing net share ownership. Importantly, the activity occurred pursuant to a pre-established Rule 10b5-1 trading plan, suggesting the timing was pre-arranged, which typically reduces informational value about the insider’s short-term view.

Following these trades, Cross holds 105,341 common shares directly, and the derivative summary in this filing shows no remaining option position from the exercised grants. Subsequent filings may give further detail on any additional grants or future 10b5-1 activity.

Insider Trade Summary 10b5-1

Net Seller: 12,059 shares ($302,598)

Net Sell 9 txns

Insider Cross Shawn

Role Chief Financial Officer

Sold 12,059 shs ($303K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,500	$0.00	--
Exercise	Common Stock	1,500	$16.45	$25K
Sale	Common Stock	1,500	$25.01	$38K
Exercise	Stock Option (Right to Buy)	2,845	$0.00	--
Exercise	Common Stock	2,845	$16.45	$47K
Sale	Common Stock	2,845	$25.01	$71K
Exercise	Stock Option (Right to Buy)	7,714	$0.00	--
Exercise	Common Stock	7,714	$16.45	$127K
Sale	Common Stock	7,714	$25.14	$194K

Holdings After Transaction: Stock Option (Right to Buy) — 162,941 shares (Direct, null); Common Stock — 106,841 shares (Direct, null)

Footnotes (1)

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cross Shawn

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		M		7,714(1)	A	$16.45	113,055	D
Common Stock	04/20/2026		S		7,714(1)	D	$25.14(2)	105,341	D
Common Stock	04/21/2026		M		2,845(1)	A	$16.45	108,186	D
Common Stock	04/21/2026		S		2,845(1)	D	$25.01(3)	105,341	D
Common Stock	04/22/2026		M		1,500(1)	A	$16.45	106,841	D
Common Stock	04/22/2026		S		1,500(1)	D	$25.01(3)	105,341	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.45	04/20/2026		M			7,714(1)	(4)	11/04/2034	Common Stock	7,714(1)	$0	167,286	D
Stock Option (Right to Buy)	$16.45	04/21/2026		M			2,845(1)	(4)	11/04/2034	Common Stock	2,845(1)	$0	164,441	D
Stock Option (Right to Buy)	$16.45	04/22/2026		M			1,500(1)	(4)	11/04/2034	Common Stock	1,500(1)	$0	162,941	D

Explanation of Responses:

1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive.

4. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Pacira BioSciences (PCRX) CFO Shawn Cross report?

Pacira CFO Shawn Cross reported exercising stock options for 12,059 common shares at an exercise price of $16.45 and selling 12,059 shares in open-market trades at weighted average prices around $25 per share over April 20–22, 2026.

How many Pacira (PCRX) shares does the CFO hold after these Form 4 transactions?

After completing the reported option exercises and related open-market sales, Pacira BioSciences CFO Shawn Cross directly holds 105,341 shares of Pacira common stock, according to the Form 4’s post-transaction ownership figures disclosed for his non-derivative holdings.

Were Pacira (PCRX) CFO Shawn Cross’s share sales under a Rule 10b5-1 plan?

Yes. A footnote explains that the option exercises and share sales were executed under a Rule 10b5-1 trading plan previously adopted by Shawn Cross in accordance with the Securities Exchange Act of 1934’s Rule 10b5-1 framework.

What prices did the Pacira (PCRX) CFO receive for the shares sold?

The filing reports weighted average sale prices. Shares sold on April 20, 2026, averaged $25.14 per share, and other sales were executed in multiple trades with prices generally ranging from $25.00 to about $25.31 per share.

What was the exercise price of the Pacira (PCRX) stock options exercised by the CFO?

The stock options exercised by Pacira CFO Shawn Cross had an exercise, or strike, price of $16.45 per share, allowing him to acquire common stock below the approximate $25 per share weighted average prices at which he subsequently sold shares.

When do the exercised Pacira (PCRX) stock options expire?

The derivative entries show that the exercised stock options, described as a “Stock Option (Right to Buy)” underlying Pacira common stock, carry an expiration date of November 4, 2034, indicating a long-dated grant that had become exercisable before these transactions.